(THRM) Gentherm - NASDAQ
Sector: Consumer Cyclical | Industry: Auto Parts | Exchange: NASDAQ (USA) | Market Cap: 1.112m USD | Total Return: 30.9% in 12m
Avg Turnover: 9.32M
EPS Trend: -20.0%
Qual. Beats: 1
Rev. Trend: 72.7%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Gentherm Inc (THRM) is a global manufacturer specializing in thermal management and pneumatic comfort technologies for the automotive and medical sectors. The company’s automotive segment provides seat heaters, steering wheel heaters, and integrated pneumatic lumbar and massage systems. Its medical division focuses on patient temperature management systems, such as hyper-hypothermia therapy devices used in surgical and intensive care environments.
The business model relies heavily on long-term contracts with light vehicle original equipment manufacturers (OEMs) and Tier 1 suppliers. In the automotive sector, thermal efficiency is increasingly critical as electric vehicle manufacturers seek to optimize battery range by using localized occupant heating rather than energy-intensive cabin-wide HVAC systems. Gentherm further supports this transition through its battery performance solutions, which include cell connecting devices and thermal management products for high-voltage battery systems.
Investors can evaluate the companys valuation metrics and historical performance in greater detail on ValueRay. Founded in 1991 and headquartered in Michigan, Gentherm maintains a diverse geographic footprint with manufacturing and development facilities across North America, Europe, and Asia.
- Global light vehicle production volumes dictate core climate comfort system revenue
- Electric vehicle battery thermal management adoption drives long-term margin expansion
- Input cost volatility in electronics and cables impacts automotive segment profitability
- OEM adoption of pneumatic massage and lumbar systems increases content per vehicle
- Medical segment demand for patient temperature management provides steady non-automotive diversification
| Net Income: 22.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 3.34 > 1.0 |
| NWC/Revenue: 26.57% < 20% (prev 28.25%; Δ -1.68% < -1%) |
| CFO/TA 0.09 > 3% & CFO 125.1m > Net Income 22.6m |
| Net Debt (150.4m) to EBITDA (129.7m): 1.16 < 3 |
| Current Ratio: 1.97 > 1.5 & < 3 |
| Outstanding Shares: last quarter (30.8m) vs 12m ago -0.07% < -2% |
| Gross Margin: 23.62% > 18% (prev 25.04%; Δ -1.43% > 0.5%) |
| Asset Turnover: 110.6% > 50% (prev 108.2%; Δ 2.45% > 0%) |
| Interest Coverage Ratio: 5.83 > 6 (EBIT TTM 75.1m / Interest Expense TTM 12.9m) |
| A: 0.29 (Total Current Assets 826.2m - Total Current Liabilities 418.4m) / Total Assets 1.43b |
| B: 0.50 (Retained Earnings 718.3m / Total Assets 1.43b) |
| C: 0.05 (EBIT TTM 75.1m / Avg Total Assets 1.39b) |
| D: 1.00 (Book Value of Equity 716.5m / Total Liabilities 713.8m) |
| Altman-Z'' = 4.93 = AAA |
| DSRI: 0.90 (Receivables 307.1m/324.6m, Revenue 1.53b/1.45b) |
| GMI: 1.06 (GM 25.04% / 23.62%) |
| AQI: 1.01 (AQ_t 0.20 / AQ_t-1 0.20) |
| SGI: 1.06 (Revenue 1.53b / 1.45b) |
| TATA: -0.07 (NI 22.6m - CFO 125.1m) / TA 1.43b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of June 10, 2026, the stock is trading at USD 36.37 with a total of 329,295 shares traded.
Over the past week, the price has changed by -2.55%,
over one month by +19.29%,
over three months by +25.15% and
over the past year by +30.92%.
Gentherm has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy THRM.
- StrongBuy: 5
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 40.6 | 11.5% |
P/E Trailing = 49.6575
P/E Forward = 13.6986
P/S = 0.7226
P/B = 1.5533
P/EG = 1.0175
Revenue TTM = 1.53b USD
EBIT TTM = 75.1m USD
EBITDA TTM = 129.7m USD
Long Term Debt = 219.0m USD (from longTermDebt, last quarter)
Short Term Debt = 9.14m USD (from shortTermDebt, last quarter)
Debt = 327.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 54.4m
Net Debt = 150.4m USD (calculated: Debt 327.8m - CCE 177.4m)
Enterprise Value = 1.26b USD (1.11b + Debt 327.8m - CCE 177.4m)
Interest Coverage Ratio = 5.83 (Ebit TTM 75.1m / Interest Expense TTM 12.9m)
EV/FCF = 16.05x (Enterprise Value 1.26b / FCF TTM 78.6m)
FCF Yield = 6.23% (FCF TTM 78.6m / Enterprise Value 1.26b)
FCF Margin = 5.12% (FCF TTM 78.6m / Revenue TTM 1.53b)
Net Margin = 1.47% (Net Income TTM 22.6m / Revenue TTM 1.53b)
Gross Margin = 23.62% ((Revenue TTM 1.53b - Cost of Revenue TTM 1.17b) / Revenue TTM)
Gross Margin QoQ = 24.70% (prev 22.02%)
Tobins Q-Ratio = 0.88 (Enterprise Value 1.26b / Total Assets 1.43b)
Interest Expense / Debt = 3.93% (Interest Expense 12.9m / Debt 327.8m)
Taxrate = 45.29% (18.7m / 41.4m)
NOPAT = 41.1m (EBIT 75.1m * (1 - 45.29%))
Current Ratio = 1.97 (Total Current Assets 826.2m / Total Current Liabilities 418.4m)
Debt / Equity = 0.46 (Debt 327.8m / totalStockholderEquity, last quarter 716.5m)
Debt / EBITDA = 1.16 (Net Debt 150.4m / EBITDA 129.7m)
Debt / FCF = 1.91 (Net Debt 150.4m / FCF TTM 78.6m)
Total Stockholder Equity = 713.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.63% (Net Income 22.6m / Total Assets 1.43b)
RoE = 3.17% (Net Income TTM 22.6m / Total Stockholder Equity 713.6m)
RoCE = 8.06% (EBIT 75.1m / Capital Employed (Equity 713.6m + L.T.Debt 219.0m))
RoIC = 4.35% (NOPAT 41.1m / Invested Capital 944.3m)
WACC = 8.84% (E(1.11b)/V(1.44b) * Re(10.81%) + D(327.8m)/V(1.44b) * Rd(3.93%) * (1-Tc(0.45)))
Discount Rate = 10.81% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -68.89 | Cagr: -2.02%
[DCF] Terminal Value 76.40% ; FCFF base≈58.8m ; Y1≈67.4m ; Y5≈99.2m
[DCF] Fair Price = 39.94 (EV 1.38b - Net Debt 150.4m = Equity 1.22b / Shares 30.7m; r=8.84% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -19.95 | EPS CAGR: -2.67% | SUE: 1.83 | # QB: 1
Revenue Correlation: 72.66 | Revenue CAGR: 1.60% | SUE: 4.0 | # QB: 2
EPS current Quarter (2026-06-30): EPS=0.56 | Chg30d=+0.59% | Revisions=-33% | Analysts=6
EPS next Quarter (2026-09-30): EPS=0.65 | Chg30d=+0.38% | Revisions=-40% | Analysts=6
EPS current Year (2026-12-31): EPS=2.71 | Chg30d=+1.66% | Revisions=+60% | GrowthEPS=+19.4% | GrowthRev=+4.2%
EPS next Year (2027-12-31): EPS=3.05 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+12.6% | GrowthRev=+6.4%
[Analyst] Revisions Ratio: +60%